T. Rowe Price Associates
CUE icon

T. Rowe Price Associates’s Cue Biopharma CUE Stock Holding History

T. Rowe Price Associates’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-608
Closed -$49K – 2963
2023
Q4 		$49K Buy
608
+53
+10% +$3.79K ﹤0.01% 2809
2023
Q3 		$39K Hold
555
– – ﹤0.01% 2801
2023
Q2 		$61K Buy
+555
New +$65.2K ﹤0.01% 2778

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates's CUE Position: Q1 2024 in Review

T. Rowe Price Associates sold out of Cue Biopharma (CUE) in Q1 2024, closing a stake of 608 shares — an estimated $49K sold.

T. Rowe Price Associates first reported a position in CUE in Q2 2023 and held it in 3 quarters. The position peaked at $61K in Q2 2023. 74 funds tracked by Wall St. Rank hold CUE as of Q1 2024.

  • T. Rowe Price Associates reported no remaining Cue Biopharma position as of Q1 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 608 Cue Biopharma shares in Q1 2024, an estimated $49K.
  • T. Rowe Price Associates first reported a position in Cue Biopharma in Q2 2023 and held it in 3 quarters.
  • T. Rowe Price Associates's Cue Biopharma position peaked at $61K in Q2 2023.
  • 74 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2024.

Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.